Oncaidia's best practice
Wednesday, 30 July, 2008
Adelaide biotech Oncaidia [ASX: ONA] has been awarded an Asia-Pacific Frost & Sullivan Technology Innovation Award for its Apomab monoclonal antibody technology.
The award celebrates innovative work in the field of cancer diagnosis and therapy.
Oncadia was awarded it for the company's proprietary Apomab technology, which is used for detection, treatment and assessment of a range of cancers including lung, breast and prostate.
Apomab is able to identify the presence of the La protein, an autoantigen that is also overexpressed in cancer cells.
The technology promises to target cancers more accurately, reducing side effects and providing more effective treatment.
Clinical trials of Apomab are set to commence shortly.
Frost & Sullivan conduct Best Practices Awards annually. The winners are determined by industry analysts in a thorough comparison process.
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
